Adebrelimab+RGL-270
Phase 1Monoclonal antibody
Adebrelimab+RGL-270 is one of 25 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Yervoy
Bristol-Myers SquibbPreclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Lenvima
EisaiPreclinical
Gilotrif
Boehringer IngelheimPreclinical
Ofev
Boehringer IngelheimPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
REGN2810
RegeneronPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Immune Checkpoint Inhibitor
IImmuneSensor Therapeutics Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adebrelimab+RGL-270. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 1[1]
- Company
- NNanjing Tianyinshan Hospital